41805-36-1

Usage

Uses

Used in Pharmaceutical Industry:
C-(1-PIPERIDIN-1-YL-CYCLOHEXYL)-METHYLAMINE is used as a key intermediate in the synthesis of various pharmaceutical compounds for its ability to contribute to the development of new drugs and treatments. Its unique structure allows for the creation of molecules with specific therapeutic properties, addressing a variety of medical conditions.
Used in Agrochemical Industry:
In the agrochemical sector, C-(1-PIPERIDIN-1-YL-CYCLOHEXYL)-METHYLAMINE serves as a crucial component in the formulation of agrochemical products. Its incorporation aids in enhancing the effectiveness of these products, contributing to improved crop protection and management strategies.
It is imperative to handle C-(1-PIPERIDIN-1-YL-CYCLOHEXYL)-METHYLAMINE with care due to its potential harmful effects if not used properly, ensuring safety in both research and industrial applications.

InChI:InChI=1/C12H24N2/c13-11-12(7-3-1-4-8-12)14-9-5-2-6-10-14/h1-11,13H2

Upstream product

• 3867-15-0 1-piperidinocyclohexylcarbonitrile 
• 108-94-1 cyclohexanone 
• 110-89-4 piperidine 

Downstream Products

• 131815-14-0 2-(3,4-Dichloro-phenyl)-N-(1-piperidin-1-yl-cyclohexylmethyl)-acetamide 
• 150208-74-5 N-[2-(3,4-Dichloro-phenyl)-ethyl]-N-(1-piperidin-1-yl-cyclohexylmethyl)-formamide 
• 150208-50-7 [2-(3,4-Dichloro-phenyl)-ethyl]-(1-piperidin-1-yl-cyclohexylmethyl)-amine 
• 41805-39-4 1-[1-(formamidomethyl)cyclohexyl]piperidine 
• 41805-45-2 1-[1-(3,4,5-trimethoxybenzamidomethyl)cyclohexyl]piperidine hydrochloride 
• 1334308-71-2 C₂₁H₃₂N₂O₂ 

Relevant academic research and scientific papers

Discovery of a novel series of selective HCN1 blockers

The discovery of a series of novel, potent, and selective blockers of the cyclic nucleotide-modulated channel HCN1 is disclosed. Here we report an SAR study around a series of selective blockers of the HCN1 channel. Utilization of a high-throughput VIPR assay led to the identification of a novel series of 2,2-disubstituted indane derivatives, which had moderate selectivity and potency at HCN1. Optimization of this hit led to the identification of the potent, 1,1-disubstituted cyclohexane HCN1 blocker, 2-ethoxy-N-((1-(4- isopropylpiperazin-1-yl)cyclohexyl)methyl)benzamide. The work leading to the discovery of this compound is described herein.

Synthesis and Evaluation of Conformationally Restricted N--N-methyl-2-(1-pyrrolidinyl)ethylamines at ? Receptors. 2. Piperazines, Bicyclic Amines, Bridged Bicyclic Amines, and Miscellaneous Compounds

As a continuation of our earlier study (J.Med.Chem. 1992, 35, 4334-4343) we conformationally restricted the ?-receptor ligand 2-(1-pyrrolidinyl)-N--N-methylethylamine (1) by incorporating it into a series of homologous piperazines 3-9 and homopiperazines 10 and 11, diazabicyclononanes and decanes, bridgehead bicyclooctanes and nonanes as well as other miscellaneous compounds. ?-Receptor binding affinites were obtained using (+)-pentazocine in guinea pig brain membrane ?1 sites.The studies suggest that the nitrogen lone pair orient ation found in the piperazines affords the strongest binding interaction.Other nitrogen lone pair orientations or compounds representing unlikely staggered conformations of 1 -1,4-diazabicyclononane (16)> show very weak ? interaction.Comperison of the binding data of different N-substituted homologues of 1 with those of the 1--4-alkylpiperazines suggests that the two nitrogen atoms of 1 are working in opposition to one another in terms of their sensitivity to steric bulk.The high binding affinity of the 1,4-diazabicyclononanes 12 suggests that these may approximate the methyl and pyrrolidine ring conformations found in 1 when it is bound to the ? receptor.Compound 12 exhibited a 4-fold enantioselectivity favoring (+)-12.The synthesis of 6,7-dichloro-2-amino>tetralin (19) and its desmethyl derivative 20 permitted constraint of the 3,4-dichlorophenyl and N-methyl moieties of 1 into a gauche orientation.The binding data suggests that this conformation in 1 favors strong binding interaction at ?-receptors. ?-Receptor K1's ra nged from 0.55 nM for 1--4-n-butylpiperazine (7) to 654 nM for 16.Overall comparison of the results indicate that 1 is subject to considerable conformational freedom and suggests that the ?-receptor is not subject to rigid stereochemical restraints with 1.These results add to our earlier study where we restrained 1 using simple monocyclic heterocycles.

1-(3,4-DICHLOROBENZAMIDOMETHYL)-CYCLOHEXYLDIMETHYLAMINE

Compounds of the general formula I: EQU1 in which R1 - R4 which may be the same or different represent hydrogen atoms, or C1-6 straight or branched chain alkyl, alkenyl or alkynyl group or an alkyl group substituted by a cycloalkyl group, or represents a cycloalkyl, alkoxycarbonyl, aryl, arakyl, acyl (which includes anylsulphonyl) groups in which the alkyl group or the alkyl portion of the aralkyl group may be substituted with one or more hydroxy or esterified hydroxy groups and in which the aryl groups or the aryl portion of the acyl or aralkyl group may be substituted by one or more halogen atoms, alkyl groups, hydroxy groups, alkoxy groups, trifluoromethyl, nitro, amino or dialkylamino groups, and in which R5 - R8 which may be the same or different represent hydrogen atoms or alkyl groups except that not all groups may be hydrogen, or R5 and R6 or R7 and R8 together represent a carbonyl (=O) oxygen and in any of the pairs of groups R1 /R2, R3 /R4, R5 /R6 and R7 /R8 may represent a carbocyclic or heterocyclic ring system optionally substituted by lower alkyl or aryl groups, said ring being saturated or unsaturated. These compounds have utility as oral analgesics.